Citius Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
Citius Pharmaceuticals, Inc. (CTXR) reported Deferred Income Tax Expense (Benefit) of -$74.32 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$107.35K, a 140.62% decline year-over-year.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$231.21K, a 187.50% decline year-over-year.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $264.24K, a 0.00% change year-over-year.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $264.24K, a 83.50% increase year-over-year.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2025 was $1.06M, a 83.50% increase from fiscal 2024.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2024 was $576.00K, a 0.00% change from fiscal 2023.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2023 was $576.00K, a 0.00% change from fiscal 2022.
- Citius Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2022 was $576.00K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$107.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$338.56K derived: sum of 2 quarters · filed 2026-08-14 | -$74.32K 10-Q · filed 2026-08-14 | $189.92K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$231.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $33.03K 10-Q · filed 2026-05-15 | $297.27K derived: sum of 3 quarters · filed 2026-05-15 | $561.51K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $264.24K 10-Q · filed 2026-02-13 | $528.48K derived: sum of 2 quarters · filed 2026-02-13 | $792.72K derived: sum of 3 quarters · filed 2026-08-14 | $1.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $264.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $528.48K derived: sum of 2 quarters · filed 2026-08-14 | $792.72K derived: sum of 3 quarters · filed 2026-08-14 | $1.06M 10-K · filed 2025-12-23 |
| 2025-06-30 | $264.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $528.48K derived: sum of 2 quarters · filed 2026-08-14 | $792.72K 10-Q · filed 2026-08-14 | $936.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $264.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $528.48K 10-Q · filed 2026-05-15 | $672.48K derived: sum of 3 quarters · filed 2026-05-15 | $816.48K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $264.24K 10-Q · filed 2026-02-13 | $408.24K derived: sum of 2 quarters · filed 2026-02-13 | $552.24K derived: sum of 3 quarters · filed 2026-02-13 | $696.24K derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $288.00K derived: sum of 2 quarters · filed 2025-12-23 | $432.00K derived: sum of 3 quarters · filed 2025-12-23 | $576.00K 10-K · filed 2025-12-23 |
| 2024-06-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $288.00K derived: sum of 2 quarters · filed 2025-08-12 | $432.00K 10-Q · filed 2025-08-12 | $576.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $288.00K 10-Q · filed 2025-05-14 | $432.00K derived: sum of 3 quarters · filed 2025-05-14 | $576.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $144.00K 10-Q · filed 2025-02-14 | $288.00K derived: sum of 2 quarters · filed 2025-02-14 | $432.00K derived: sum of 3 quarters · filed 2025-02-14 | $576.00K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $288.00K derived: sum of 2 quarters · filed 2024-12-27 | $432.00K derived: sum of 3 quarters · filed 2024-12-27 | $576.00K 10-K · filed 2024-12-27 |
| 2023-06-30 | $144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-12 | $288.00K derived: sum of 2 quarters · filed 2024-08-12 | $432.00K 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-14 | $288.00K 10-Q · filed 2024-05-14 | ||
| 2022-12-31 | $144.00K 10-Q · filed 2024-02-14 | |||
| 2022-09-30 | $576.00K 10-K · filed 2023-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |